65 results
8-K
EX-10.1
BIAF
BioAffinity Technologies Inc
5 Jun 24
Departure of Directors or Certain Officers
4:10pm
with its authority under Section 3.2 hereof. An Award may consist of one type of right or benefit hereunder or of two or more such rights or benefits … Events/Representations. The Committee may specify in an Award Agreement at the time of the Award that the Participant’s rights, payments, and benefits
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from … costs and benefits as we added research personnel, as well as a related increase in costs for lab supplies and reagents.
Clinical Development
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could … %, for the three months ended March 31, 2024, compared to the same period in 2023 was primarily due to an increase in compensation costs and benefits
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
, compared with $20,000 for the first quarter of 2023. The increase was primarily due to an increase in compensation costs and benefits from the addition
424B3
2vqgj53t9laobyjwz
16 Apr 24
Prospectus supplement
7:19pm
POS AM
7t2jlb yru234
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-99.1
vb7lbsv9livsu
1 Apr 24
Results of Operations and Financial Condition
4:00pm
8-K
EX-4.1
7c8v2lzi
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-1.1
x0ydlu0182oky7z rt
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
s8gy xttl72dixb
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
tmj wrw44hpn
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
fio mb9pm4xg
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-10.1
f1s0bvf6evzzb dqv17
31 Jan 24
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
m1bmi7b1x 3s0g
5 Dec 23
Departure of Directors or Certain Officers
8:45am